Natera, Illumina Expand Supply Agreement to Include Oncology IVDs

Jun 14, 2016

|

NEW YORK (GenomeWeb) – Natera and Illumina have extended and expanded their supply agreement, through which Natera purchases Illumina's products, until June 8, 2026, according to a document filed this week with the US Securities and Exchange Commission.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Natera, Illumina Expand Supply Agreement to Include Oncology IVDs

To read the full story....

Breaking News

FDA Adds At-Home Self-Collection Template to SARS-CoV-2 Emergency Use Authorization Guidance

BTIG Initiates Coverage of Fulgent Genetics

Tangen Biosciences, LabWare Partner on Point-of-Care Coronavirus Kit

Progenity Files for IPO, Seeks to Raise up to $100M

LetsGetChecked At-Home Molecular SARS-CoV-2 Test Nabs FDA Emergency Use Authorization

OraSure Technologies to Acquire HIV Drug Adherence Test Developer UrSure

Featured White Papers

COVID-19 Testing, Treatment and Future Outlook

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

What's Popular?

LetsGetChecked At-Home Molecular SARS-CoV-2 Test Nabs FDA Emergency Use Authorization

AMP SARS-CoV-2 Molecular Dx Survey Shows Supply Chain Issues Hampered Ramp Up of Testing

FDA Releases Reference Panel for Coronavirus Test Developers

Progenity Files for IPO, Seeks to Raise up to $100M

With Low-Cost SARS-CoV-2 Assay, FYR Diagnostics Looks to Bypass Equipment Bottlenecks

Sponsorships